A detailed history of Massachusetts Financial Services CO transactions in Alkermes Plc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 52,977 shares of ALKS stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,977
Previous 53,095 0.22%
Holding current value
$1.29 Million
Previous $1.47 Million 2.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$26.4 - $32.56 $3,115 - $3,842
-118 Reduced 0.22%
52,977 $1.43 Million
Q4 2023

Feb 08, 2024

SELL
$23.37 - $28.68 $39,168 - $48,067
-1,676 Reduced 3.06%
53,095 $1.47 Million
Q3 2023

Nov 08, 2023

SELL
$27.17 - $31.97 $57,002 - $67,073
-2,098 Reduced 3.69%
54,771 $1.53 Million
Q2 2023

Aug 09, 2023

BUY
$28.34 - $33.63 $933,264 - $1.11 Million
32,931 Added 137.57%
56,869 $1.78 Million
Q1 2023

May 10, 2023

SELL
$25.31 - $29.02 $17,109 - $19,617
-676 Reduced 2.75%
23,938 $674,000
Q4 2022

Feb 13, 2023

BUY
$21.94 - $26.24 $11,452 - $13,697
522 Added 2.17%
24,614 $643,000
Q3 2022

Nov 09, 2022

BUY
$22.0 - $31.87 $530,024 - $767,812
24,092 New
24,092 $538,000
Q1 2022

May 11, 2022

SELL
$23.07 - $27.99 $1.93 Million - $2.35 Million
-83,794 Closed
0 $0
Q4 2021

Feb 10, 2022

SELL
$21.47 - $32.08 $36,456 - $54,471
-1,698 Reduced 1.99%
83,794 $1.95 Million
Q3 2021

Nov 10, 2021

BUY
$23.37 - $32.13 $351,835 - $483,717
15,055 Added 21.37%
85,492 $2.64 Million
Q2 2021

Aug 13, 2021

BUY
$18.78 - $25.15 $11,343 - $15,190
604 Added 0.86%
70,437 $1.73 Million
Q1 2021

May 13, 2021

BUY
$18.21 - $23.2 $1.27 Million - $1.62 Million
69,833 New
69,833 $1.3 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.